El-Ghamrawy Affirms the Authority's Support for National Industry.. Novartis Praises the Authority's Role in Promoting Investment and Overcoming Obstacles.
…………….
Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA), held an official meeting with a delegation from Novartis to strengthen strategic cooperation with leading global pharmaceutical companies, in a way that supports the development of the pharmaceutical industry and boosts the national economy.
The meeting discussed Novartis’s performance in the Egyptian market and its future plans to expand production lines and localize the company’s products. The company affirmed its commitment to supporting local industry and increasing export opportunities, contributing to the availability of high-quality medicines for both the Egyptian and regional markets.
During the meeting, Dr. Ali El-Ghamrawy stressed the EDA’s commitment to continued cooperation with manufacturers and to providing all possible support to develop the national pharmaceutical industry. He highlighted the importance of this vital sector in supporting the national economy and enhancing Egypt’s capabilities in healthcare. He also emphasized the need to expand local production to reduce dependence on imports and increase export opportunities to regional and international markets, which would boost the competitiveness of Egyptian pharmaceutical products and achieve self-sufficiency, positively impacting public health and supporting the state's efforts to achieve sustainable development in this strategic sector.
He noted that the Authority is continuously updating its mechanisms and procedures in alignment with international standards, aiming to encourage investment in the pharmaceutical field and localize the latest pharmaceutical manufacturing technologies in Egypt.
For their part, Novartis representatives expressed deep appreciation for the pivotal role played by the Egyptian Drug Authority in supporting the pharmaceutical industry and removing obstacles facing investors. They praised the Authority’s dedication to enhancing collaboration with global pharmaceutical companies and providing a flexible, advanced regulatory environment that promotes increased production and supports export plans, benefiting both the Egyptian patient and regional markets.
From the Egyptian Drug Authority , the meeting was attended by Dr. Amany Gawdat, Associate to the EDA Chairman and Supervisor of the Central Administration of the Chairman Office , and Dr. Osama Hatem, Associate to the EDA Chairman for Policy and International Cooperation and Supervisor of the Central Administration of Pharmaceutical Policies and Market Access.
From Novartis, the attendees included Dr. Gihan El-Mor, Chairperson and Managing Director, Dr. Rania Ashraf, Head of Government Affairs for the Middle East, Dr. Amr Nasr, Head of External Relations, and Dr. Naglaa Fathy, Head of Registration at the company.
This meeting comes within the framework of the effective partnership between the Authority and the pharmaceutical industrial sector, aiming to ensure the availability of safe and effective medicines for Egyptian patients and enhance the competitiveness of local pharmaceutical products in foreign markets, achieving a qualitative leap in the level of local manufacturing in accordance with the latest global quality standards.